YOLFTbeta
Medicenna Therapeutics Corp

Medicenna Therapeutics Corp

MDNA · TO · Healthcare / Biotechnology

0.385CAD-0.01 (-1.28%)

Price History

Full chart

Market Stats

Previous Close0.39
Open0.435
Day Range0.365 – 0.435
52-Week Range0.335 – 1.97
Volume66.95K
Market Cap35.54M
P/E (TTM)0.00
Forward P/E232.56
EPS-0.22
Dividend Yield0.00%
Beta1.96
50-Day Avg0.4112
200-Day Avg0.606

About

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkine for cancer. In addition, its preclinical products are MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases, including transplant rejection; and MDNA413, an IL-4/IL-13 antagonist to inflammatory, asthma, and atopic dermatitis, as well as other allergic diseases. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Fahar Merchant Ph.D.
  • Employees15
  • Headquarters2 Bloor Street West, Toronto, ON, Canada, M4W 3E2, Canada
  • Websitehttps://www.medicenna.com

Leadership

  • Dr. Fahar Merchant Ph.D.Founder, Chairman, President & CEO · b. 1957
  • Ms. Rosemina Merchant B.Sc., M.E.ScFounder & Chief Development Officer · b. 1957
  • Mr. David Hyman CA, CBVChief Financial Officer · b. 1973
  • Dr. Nageatte Ibrahim M.D.Chief Medical Officer
  • Dr. Samuel R. Denmeade M.D.Scientific Advisor

Financials

Income Statement

Currency: CAD2014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Revenue0000000000000
Cost of Revenue001.44K6.49K9.70K6.82K7.89K40.00K38.00K5.00K5.00K55.00K77.00K
Gross Profit00-1.44K-6.49K-9.70K-6.82K-7.89K-40.00K-38.00K-5.00K-5.00K-55.00K-77.00K
Operating Expense762.00K829.11K1.20M7.69M7.42M4.72M8.20M17.15M22.26M21.64M19.66M21.58M23.63M
Operating Income-762.00K-829.11K-1.20M-7.70M-7.42M-4.73M-8.21M-17.19M-22.30M-21.64M-19.66M-21.63M-23.71M
EBITDA-3.77K-828.39K-1.20M-7.62M-7.46M-4.70M-8.27M-17.25M-22.54M-16.30M-18.67M-12.97M-23.63M
Net Income-765.77K-833.49K-1.33M-7.63M-7.47M-4.71M-8.31M-17.18M-22.65M1.55M-25.47M-11.80M-18.41M
R&D860.96K766.30K771.41K4.23M5.09M3.02M5.87M10.87M14.72M9.30M11.79M15.67M18.18M
Interest Expense00.184416040.62K19.25K0069.00K11.60M---

Balance Sheet

Currency: CAD2014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Assets562.85K272.56K5.76M14.48M4.37M5.19M38.00M42.25M23.46M36.45M19.13M28.38M8.45M
Total Liabilities829.89K291.87K3.51M7.83M2.21M2.57M1.85M4.11M2.62M6.96M13.94M9.29M5.97M
Total Equity-267.05K-19.30K2.24M6.66M2.16M2.62M36.15M38.15M20.84M29.49M5.19M19.09M2.48M
Cash3.91K125.56K5.34M14.04M3.94M2.37M22.70M30.38M20.54M33.60M16.98M24.84M6.25M
Total Debt378.88K-1.46M---67.31K34.00K---168.00K119.00K
Net Debt374.98K-125.56K-3.88M-14.04M-3.94M-2.37M-22.63M-30.34M-20.54M-33.60M-16.98M-24.67M-6.13M

Cash Flow

Currency: CAD2014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Operating Cash Flow-619.44K-880.32K-2.57M-7.31M-10.12M-8.04M-8.95M-15.31M-23.58M-12.66M-16.26M-16.49M-17.92M
Investing Cash Flow-2.15K-2.15K1.08M603.14K-140.03K-354.46K-15.00M5.01M10.05M-13.05M--33.00K2.00K
Financing Cash Flow259.58K1.00M7.85M15.39M469.39K6.82M44.28M18.26M3.88M24.76M023.49M-19.00K
Capital Expenditure2.15K2.15K5.38K5.38K000000033.00K17.92M
Free Cash Flow-619.44K-882.47K-2.57M-7.31M-10.12M-8.04M-8.95M-15.31M-23.58M-12.66M-16.26M-16.52M-17.92M
FCF to OCF100.00%100.24%100.00%100.07%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.20%100.00%

Earnings

Report DateJun 30, 2016Sep 30, 2016Dec 31, 2016Apr 20, 2017Sep 8, 2017Nov 13, 2017Feb 12, 2018Jun 27, 2018Aug 13, 2018Nov 13, 2018Feb 14, 2019Jun 24, 2019Aug 9, 2019Nov 5, 2019Feb 13, 2020May 15, 2020Aug 4, 2020Nov 13, 2020Feb 12, 2021May 28, 2021Aug 13, 2021Nov 12, 2021Feb 9, 2022Jun 22, 2022Aug 15, 2022Nov 4, 2022Feb 7, 2023Jun 27, 2023Jul 28, 2023Nov 14, 2023Feb 14, 2024Jun 27, 2024Jul 31, 2024Nov 14, 2024Feb 12, 2025Jun 25, 2025Jul 29, 2025Nov 12, 2025Feb 12, 2026Jun 25, 2026Aug 13, 2026Nov 12, 2026
EPS Estimate------0.14-0.14-0.11--0.04-0.04-0.14-0.08-0.10-0.09-0.04-0.03-0.09-0.06-0.11-0.10-0.12-0.13-0.11-0.08-0.07-0.08-0.08-0.08-0.07-0.08-0.05-0.06-0.06-0.07-0.05-0.05-0.07-0.06-0.06-0.06-0.04
EPS Actual-0.13-0.81-1.88-0.23-0.09-0.07-0.09-0.05-0.04-0.04-0.07-0.03-0.05-0.07-0.07-0.07-0.05-0.08-0.11-0.11-0.12-0.15-0.09-0.06-0.07-0.07-0.07-0.06-0.06-0.05-0.07-0.20-0.05-0.05-0.070.02-0.06-0.06-0.05-0.05-0.06-
Surprise-----49.57%35.71%54.55%-0.00%-75.00%78.57%37.50%30.00%22.22%-75.00%-66.67%11.11%-83.33%0.00%-20.00%-25.00%30.77%45.45%12.50%0.00%12.50%25.00%25.00%28.57%12.50%-300.00%16.67%16.67%0.00%140.00%-20.00%14.29%16.67%16.67%0.00%-
Timing---After-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap35.54M
Enterprise Value31.79M
Trailing P/E0.00
Forward P/E232.56
Price / Sales0.00
Price / Book22.34
EPS-0.22
Book Value0.018
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-22.36M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-227.57%
Return on Assets-90.10%
Shares Outstanding92.30M
Shares Float74.34M
Beta1.96
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Mar 3, 20171:14